NCT00740779

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: Watson Pharmaceuticals · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.

Detailed description

A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Conditions

• Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Interventions

Type	Name	Description
DRUG	Silodosin 8 mg	Silodosin 8 mg daily
DRUG	Placebo	Placebo
DRUG	Silodosin 4 mg	Silodosin 4 mg daily

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2008-08-25
• Last updated: 2012-02-24
• Results posted: 2012-02-24

Locations

22 sites across 1 country: United States